[心房动中的XI因子抑制:我们处于何处?]
Simona Giubilato1, Davide Capodanno2
1U.O.C. di UTIC con Cardiologia ed Emodinamica, AOE Cannizzaro, Catania.
概括
XI因子 (FXI) 抑制剂在预防血栓和降低出血风险方面表现有前途. 然而,临床试验显示,它们的有效性得到了不同的结果,需要对心房的治疗进行进一步的研究.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 十一因子 (FXI) 是新型抗凝剂的关键点.
- FXI 抑制剂旨在减少血栓栓塞,其安全性比传统抗凝剂更好.
- 各种FXI抑制剂类正在开发中,包括小分子和生物制剂.
研究的目的:
- 审查FXI抑制的病理生理基础.
- 描述不同的FXI抑制剂子类.
- 总结临床试验数据,概述FXI抑制剂在血栓塞栓预防中的未来前景,特别是对心房动 (AF).
主要方法:
- 已完成和正在进行的临床试验的审查.
- 对FXI的药理抑制策略的分析.
- 检查二期和三期研究的安全性和有效性数据.
主要成果:
- 第二阶段试验表明FXI抑制剂的安全性概况有利.
- 疗效数据仍然不确定;一些试验因劣势或早期终止而停止,以减少出血.
- 目前正在进行的试验对于确定FXI抑制剂的确切作用至关重要.
结论:
- FXI 抑制剂代表了对血栓栓塞性疾病的潜在治疗创新.
- 需要进一步的证据来确认FXI抑制剂在临床实践中的有效性和安全性,特别是在AF.
- 在抗凝固疗法中FXI抑制剂的最终作用尚未确定.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis III: Interprofessional Care
400
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
400
Clot Retraction and Fibrinolysis
9.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Extrinsic and Intrinsic Pathways of Hemostasis
14.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.0K


